Autres langues eFFECTOR Therapeutics, Inc.

Actions

EFTR

US28202V2079

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
2,2 ^USD	+1,85%		+16,40%	-81,17%

04/04	Les plus fortes baisses de la mi-journée	MT
04/04	EFFECTOR Therapeutics, Inc. annonce les premiers résultats de l'essai de phase 2 KICKSTART sur le tomivosertib associé au pembrolizumab dans le traitement du cancer du poumon non à petites cellules	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Health Care Down on Retreat From Risk -- Health Care Roundup	04/04
Top Midday Decliners	04/04
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04
Top Premarket Decliners	26/03
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	25/03
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	05/02
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	25/01
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09/01
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09/01
EFFECTOR Therapeutics Announces Reverse Stock Split	09/01
EFFECTOR Therapeutics Announces Reverse Stock Split	09/01
EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA FROM DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN ER+ METASTATIC BREAST CANCER PATIENTS	11/12
EFFECTOR Therapeutics Says Study of Zotatifin in Breast Cancer Patients Yields 'Positive' Interim Data	08/12
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	08/12
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	08/12
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients	08/12
EFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer	28/11
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer	28/11
The role of STRIs in cancer	27/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues eFFECTOR Therapeutics, Inc.

Actions

EFTR

US28202V2079

Autres langues

Filtres